Sp1 transcription factor as a molecular target for nitric oxide- and cyclic nucleotide-mediated suppression of cGMP-dependent protein kinase-Iα expression in vascular smooth muscle cells

Hassan Sellak, Xiangli Yang, Xu Cao, Trudy Cornwell, Gerald A. Soff, Thomas Lincoln

Research output: Contribution to journalArticle

58 Citations (Scopus)

Abstract

cGMP-dependent protein kinase (PKG) expression is highly variable and decreases in cultured vascular smooth muscle cells (VSMCs), exposure of cells to nitric oxide (NO), or in response to balloon catheter injury in vivo. In this study, the mechanisms of human type I PKG-α (PKG-Iα) gene expression were examined. Three structurally unrelated NO donors decreased PKG-Iα promoter activity after transfection of a promoter/luciferase construct in VSMCs. Promoter deletion analysis demonstrated that (1) a 120-bp promoter containing tandem Sp1 sites was sufficient to drive basal PKG-Iα promoter activity, and (2) NO was inhibitory at this site. Cyclic nucleotide analogues also suppressed PKG-Iα promoter activity with cAMP being more potent than cGMP. The effects of cyclic nucleotides to suppress PKG-Iα promoter activity were attenuated by a specific cAMP-dependent protein kinase (PKA) inhibitor. Single or double mutation of Sp1 binding sites abolished PKG-Iα expression. Moreover, Sp1 binding activity on the PKG-Iα promoter was detected in A7r5 cells, and this binding was inhibited by NO and cyclic nucleotides. These results indicate that PKG-Iα gene expression is driven by an Sp1 transcription mechanism, and that NO and cAMP inhibit Sp1-mediated PKG-Iα gene expression through separate mechanisms.

Original languageEnglish (US)
Pages (from-to)405-412
Number of pages8
JournalCirculation research
Volume90
Issue number4
DOIs
StatePublished - Mar 8 2002

Fingerprint

Cyclic GMP-Dependent Protein Kinase Type I
Sp1 Transcription Factor
Cyclic Nucleotides
Vascular Smooth Muscle
Smooth Muscle Myocytes
Nitric Oxide
Gene Expression
Cyclic GMP-Dependent Protein Kinases
Nitric Oxide Donors
Protein Kinase Inhibitors
Cyclic AMP-Dependent Protein Kinases
Luciferases
Transfection
Catheters
Binding Sites
Mutation
Wounds and Injuries

Keywords

  • CGMP
  • Disease
  • Gene regulation
  • Inflammation
  • Phosphorylation

ASJC Scopus subject areas

  • Physiology
  • Cardiology and Cardiovascular Medicine

Cite this

Sp1 transcription factor as a molecular target for nitric oxide- and cyclic nucleotide-mediated suppression of cGMP-dependent protein kinase-Iα expression in vascular smooth muscle cells. / Sellak, Hassan; Yang, Xiangli; Cao, Xu; Cornwell, Trudy; Soff, Gerald A.; Lincoln, Thomas.

In: Circulation research, Vol. 90, No. 4, 08.03.2002, p. 405-412.

Research output: Contribution to journalArticle

Sellak, Hassan ; Yang, Xiangli ; Cao, Xu ; Cornwell, Trudy ; Soff, Gerald A. ; Lincoln, Thomas. / Sp1 transcription factor as a molecular target for nitric oxide- and cyclic nucleotide-mediated suppression of cGMP-dependent protein kinase-Iα expression in vascular smooth muscle cells. In: Circulation research. 2002 ; Vol. 90, No. 4. pp. 405-412.
@article{186e3618f8b64662ad4f44f7decaff3e,
title = "Sp1 transcription factor as a molecular target for nitric oxide- and cyclic nucleotide-mediated suppression of cGMP-dependent protein kinase-Iα expression in vascular smooth muscle cells",
abstract = "cGMP-dependent protein kinase (PKG) expression is highly variable and decreases in cultured vascular smooth muscle cells (VSMCs), exposure of cells to nitric oxide (NO), or in response to balloon catheter injury in vivo. In this study, the mechanisms of human type I PKG-α (PKG-Iα) gene expression were examined. Three structurally unrelated NO donors decreased PKG-Iα promoter activity after transfection of a promoter/luciferase construct in VSMCs. Promoter deletion analysis demonstrated that (1) a 120-bp promoter containing tandem Sp1 sites was sufficient to drive basal PKG-Iα promoter activity, and (2) NO was inhibitory at this site. Cyclic nucleotide analogues also suppressed PKG-Iα promoter activity with cAMP being more potent than cGMP. The effects of cyclic nucleotides to suppress PKG-Iα promoter activity were attenuated by a specific cAMP-dependent protein kinase (PKA) inhibitor. Single or double mutation of Sp1 binding sites abolished PKG-Iα expression. Moreover, Sp1 binding activity on the PKG-Iα promoter was detected in A7r5 cells, and this binding was inhibited by NO and cyclic nucleotides. These results indicate that PKG-Iα gene expression is driven by an Sp1 transcription mechanism, and that NO and cAMP inhibit Sp1-mediated PKG-Iα gene expression through separate mechanisms.",
keywords = "CGMP, Disease, Gene regulation, Inflammation, Phosphorylation",
author = "Hassan Sellak and Xiangli Yang and Xu Cao and Trudy Cornwell and Soff, {Gerald A.} and Thomas Lincoln",
year = "2002",
month = "3",
day = "8",
doi = "10.1161/hh0402.105898",
language = "English (US)",
volume = "90",
pages = "405--412",
journal = "Circulation Research",
issn = "0009-7330",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Sp1 transcription factor as a molecular target for nitric oxide- and cyclic nucleotide-mediated suppression of cGMP-dependent protein kinase-Iα expression in vascular smooth muscle cells

AU - Sellak, Hassan

AU - Yang, Xiangli

AU - Cao, Xu

AU - Cornwell, Trudy

AU - Soff, Gerald A.

AU - Lincoln, Thomas

PY - 2002/3/8

Y1 - 2002/3/8

N2 - cGMP-dependent protein kinase (PKG) expression is highly variable and decreases in cultured vascular smooth muscle cells (VSMCs), exposure of cells to nitric oxide (NO), or in response to balloon catheter injury in vivo. In this study, the mechanisms of human type I PKG-α (PKG-Iα) gene expression were examined. Three structurally unrelated NO donors decreased PKG-Iα promoter activity after transfection of a promoter/luciferase construct in VSMCs. Promoter deletion analysis demonstrated that (1) a 120-bp promoter containing tandem Sp1 sites was sufficient to drive basal PKG-Iα promoter activity, and (2) NO was inhibitory at this site. Cyclic nucleotide analogues also suppressed PKG-Iα promoter activity with cAMP being more potent than cGMP. The effects of cyclic nucleotides to suppress PKG-Iα promoter activity were attenuated by a specific cAMP-dependent protein kinase (PKA) inhibitor. Single or double mutation of Sp1 binding sites abolished PKG-Iα expression. Moreover, Sp1 binding activity on the PKG-Iα promoter was detected in A7r5 cells, and this binding was inhibited by NO and cyclic nucleotides. These results indicate that PKG-Iα gene expression is driven by an Sp1 transcription mechanism, and that NO and cAMP inhibit Sp1-mediated PKG-Iα gene expression through separate mechanisms.

AB - cGMP-dependent protein kinase (PKG) expression is highly variable and decreases in cultured vascular smooth muscle cells (VSMCs), exposure of cells to nitric oxide (NO), or in response to balloon catheter injury in vivo. In this study, the mechanisms of human type I PKG-α (PKG-Iα) gene expression were examined. Three structurally unrelated NO donors decreased PKG-Iα promoter activity after transfection of a promoter/luciferase construct in VSMCs. Promoter deletion analysis demonstrated that (1) a 120-bp promoter containing tandem Sp1 sites was sufficient to drive basal PKG-Iα promoter activity, and (2) NO was inhibitory at this site. Cyclic nucleotide analogues also suppressed PKG-Iα promoter activity with cAMP being more potent than cGMP. The effects of cyclic nucleotides to suppress PKG-Iα promoter activity were attenuated by a specific cAMP-dependent protein kinase (PKA) inhibitor. Single or double mutation of Sp1 binding sites abolished PKG-Iα expression. Moreover, Sp1 binding activity on the PKG-Iα promoter was detected in A7r5 cells, and this binding was inhibited by NO and cyclic nucleotides. These results indicate that PKG-Iα gene expression is driven by an Sp1 transcription mechanism, and that NO and cAMP inhibit Sp1-mediated PKG-Iα gene expression through separate mechanisms.

KW - CGMP

KW - Disease

KW - Gene regulation

KW - Inflammation

KW - Phosphorylation

UR - http://www.scopus.com/inward/record.url?scp=0037040834&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037040834&partnerID=8YFLogxK

U2 - 10.1161/hh0402.105898

DO - 10.1161/hh0402.105898

M3 - Article

VL - 90

SP - 405

EP - 412

JO - Circulation Research

JF - Circulation Research

SN - 0009-7330

IS - 4

ER -